Nitrated Alpha-Synuclein Peptide Immunotherapy for Parkinson's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for central nervous system disorders, particularly Parkinson's disease, are inadequate in addressing the neurodegenerative effects of nitrated alpha-synuclein and Lewy bodies, which contribute to dopaminergic neuron loss and neuroinflammation.
Innovation Solution
Administering a nitrated alpha-synuclein peptide in conjunction with an adjuvant that stimulates regulatory T cells to modulate immune responses and reduce neuroinflammatory damage, thereby inhibiting or treating central nervous system disorders characterized by nitrated alpha-synuclein and Lewy bodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for Parkinson's disease, then general symptom management is provided, but neurodegenerative processes driven by nitrated alpha-synuclein and microglial inflammation are not effectively inhibited
Solution Approach 1:
The patent utilizes nitrated alpha-synuclein, which is normally a harmful pathogenic factor causing neurodegeneration, as an immunogen to stimulate the immune system. By converting this harmful substance into a therapeutic agent that triggers immune response, the treatment turns the disease mechanism itself into a tool for fighting the disease, achieving neuroprotection through active immunization
Solution Approach 2:
The patent introduces regulatory T cells as intermediary elements that mediate between the immune system and microglia. These T cells act as regulators that suppress excessive microglial activation and oxidative stress, thereby reducing neuroinflammation while maintaining immune surveillance against nitrated alpha-synuclein
2Reliability
If immune responses are stimulated to target nitrated alpha-synuclein, then neuroprotection is enhanced, but immune system complexity and potential side effects increase
Solution Approach 1:
The patent employs adjuvants with specific local qualities that selectively stimulate regulatory T cells rather than causing generalized immune activation. The adjuvant formulation is designed to create a localized immunomodulatory environment that promotes Treg differentiation and function specifically at the site of antigen presentation, thereby enhancing neuroprotection while minimizing systemic immune complexity
Data Source
AI summary
Methods and compositions for treating central nervous system diseases and disorders are disclosed. In a particular embodiment, compositions comprising a nitrated alpha synuclein peptide are provided. The composition may further comprise an adjuvant that stimulates regulatory T cells and/or at least one pharmaceutically acceptable carrier.